SC: Externally Procured Parts Given For Assembly, Not Used in Manufacture, Not Liable to Excise Duty || SC: Upholding Surendra Koli’s Conviction on Rejected Evidence Would Violate Articles 14 and 21 || SC: In Execution Petition, Decree-Holder Must Prove Violation by Judgment Debtor || SC: Insurers Must Compensate Accident Victims Despite Policy Breach, Can Recover From Owner || Kerala HC: Long-Term Posting of Same Police Officer at Sabarimala May Affect Transparency, Efficiency || Delhi HC: Post-Dated Cheques Given as Security Attract Section 138 NI Act After Liability Arises || MP High Court: Railways Liable for Deaths on Tracks if it Fails to Take Preventive Measures || Ker HC: NDPS Case Stands Even if Contraband Listed in Ml, if Chemical Report Shows Equivalent Weight || Kerala HC: Father’s Retirement Benefits Can Be Attached for Child Maintenance Despite S.60(1)(g) CPC || Supreme Court: A Decree Declared 'Nullity' Can be Challenged at Any Stage, Including Execution

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :